Surfacide’s FDA-authorized Helios+ UV-C System is engineered to deliver whole room microbial reduction through its patented three-emitter design, providing comprehensive whole room coverage in a single cycle. Helios+ FDA authorization reflects a rigorous review process that includes validation of microbial efficacy as well as testing for electrical safety, electromagnetic compatibility, software and cybersecurity, biocompatibility, and material compatibility. Together, these evaluations provide hospitals with confidence in the performance and safety of the technology.
Engineered with workflow in mind, Helios+ features intuitive operation, real-time reporting and robust data capture. Helios+ enhances existing cleaning protocols without delaying room turnover, helping infection prevention and EVS teams achieve safer, more efficient environments of care. From operating rooms and patient rooms to specialty care spaces, Helios+ empowers hospitals to standardize whole room microbial reduction with confidence, supported by FDA authorization, patented innovation, proven performance and measurable results.
